2019
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Drilon A, Wolchok JD, Carvajal RD, McHenry MB, Hosein F, Harbison CT, Grosso JF, Sznol M. Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab. JAMA Oncology 2019, 5: 1411-1420. PMID: 31343665, PMCID: PMC6659167, DOI: 10.1001/jamaoncol.2019.2187.Peer-Reviewed Original ResearchNon-small cell lung cancerRenal cell carcinomaLong-term survivalTreatment-related AEsOverall survivalCell lung cancerAdvanced melanomaCell carcinomaLung cancerEastern Cooperative Oncology Group performance statusFuture clinical trial developmentLong-term overall survivalActivity of nivolumabSubsequent protocol amendmentUnacceptable toxic effectsFive-year survivalOverall survival curvesPresence of liverCell death 1Clinical trial developmentUS medical centersNivolumab treatmentPerformance statusProgressive diseaseBone metastasesA phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952).
Bazhenova L, Redman M, Gettinger S, Hirsch F, Mack P, Schwartz L, Gandara D, Bradley J, Stinchcombe T, Leighl N, Ramalingam S, Tavernier S, Minichiello K, Kelly K, Papadimitrakopoulou V, Herbst R. A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952). Journal Of Clinical Oncology 2019, 37: 9014-9014. DOI: 10.1200/jco.2019.37.15_suppl.9014.Peer-Reviewed Original ResearchInvestigator-assessed progression-free survivalOverall survivalInterim analysisStage IV squamous cell lung cancerSquamous cell lung cancerGrade 5 AEsImmunotherapy-naïve patientsStudies of nivolumabTreatment-related AEsPD-L1 expressionProgression-free survivalPhase IIICell lung cancerECOG 0Primary endpointRECIST 1.1Baseline characteristicsPD-L1Lung cancerLung-MAPNivolumabStage IVPatientsResponse rateMaster protocols
2012
Results of a global phase II study with crizotinib in advanced ALK -positive non-small cell lung cancer (NSCLC).
Kim D, Ahn M, Shi Y, De Pas T, Yang P, Riely G, Crinò L, Evans T, Liu X, Han J, Salgia R, Moro-Sibilot D, Ou S, Gettinger S, Wu Y, Lanzalone S, Polli A, Iyer S, Shaw A. Results of a global phase II study with crizotinib in advanced ALK -positive non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2012, 30: 7533-7533. DOI: 10.1200/jco.2012.30.15_suppl.7533.Peer-Reviewed Original ResearchNon-small cell lung cancerAdvanced ALK-positive non-small cell lung cancerALK-positive non-small cell lung cancerPatient-reported symptomsTumor responseFrequent treatment-related AEsECOG PS 0Efficacy of crizotinibPrior chemotherapy regimensTreatment-related AEsTreatment-related SAEsDisease control rateMedian treatment durationPhase II studyFavorable tolerability profileMajority of patientsCell lung cancerEnd of treatmentEORTC QLQ-C30Standard of careALK gene rearrangementHigh response rateFebrile neutropeniaLC-13Median PFS